Highlights from Masters in Thoracic Oncology Summit (MaTOS) 2024

2024 Masters in Thoracic Oncology Summit took place from November 21st to the 24th at the Ritz-Carlton Lake Tahoe, Truckee, California.

The Masters in Thoracic Oncology Summit (MaTOS) was a 3-day meeting, presented in significant distinct sessions by key thoracic oncology experts. This summit addressed and discussed the current challenges and future directions in the lung cancer space.

Through open discussions, attendees had the opportunity to analyze the latest discoveries in genetics and epigenomics in lung cancer, including diagnosis, minimal residual disease (MRD), monitoring for recurrence, and assessment of therapeutic success with targeted therapy and immunotherapy.

Stephen V Liu:

“Looking ahead for SCLC with Dr. Misty Dawn Shields at MaTOS24. Where will ADCs and BiTEs make the biggest impact? What are the optimal targets and payloads? How will maintenance lurbinectedin change outcomes? What role will radiation play?”

Estela Rodriguez:

“Zosia Piotrowska, Mass General Cancer Center gives a great overview of treatment paradigm for EGFR20ins NSCLC and future directions.

• Current SOC: amivantamab and chemo (Papilon).
• Next options: 1L TKI vs TKI and chemotherapy.
• Need to understand patters of resistance.”

Eric K. Singhi:

“So many great discussions on lung cancer screening by the panel:

Should we expand screening eligibility, and how?
What is the comfort level and trust in emerging biomarkers for screening?
How can we address incidental pulmonary nodules while minimizing harm?”

Misty Dawn Shields:

“What a lovely time at MaTOS24 with amazing colleagues, vibrant discussions, fun games, and beautiful views in Lake Tahoe!”

Estela Rodriguez:

“Stephen V Liu presents a case of HER2+ mutation PDL1+ lung cancer w multifocal progression post adjuvant chemo. Highlighting: -1st line activity of T-DXd (enherthu)- awaiting full study -poor response to IO -HER2 mutations & HER2 amplifications may respond differently to IO.”

Linda Martin:

“Connections are so important for learning and collaboration, moving the needle for better lung cancer care. A little post meeting exploration at North star Tahoe with Hatim Husain.”

Nagla Abdel Karim:

“It was such a great pleasure presenting and participating at MaTOS24 and being among my wonderful friends. Thank you ⁦Luis Raez, Edgardo S. Santos, Marina Garassino, Christine Lovly⁩ for the invite and for an outstanding meeting.”

Estela Rodriguez:

“MATOS24: Panel of experts discussing best 1st line therapy for ALK+ NSCLC– preferred choice lorlatinib but a lot of discussion of managing toxicities, dose reduction and shared decision making with patients.”

Kelly Mercier:

“While we don’t have any biomarkers in sclc, it’s not for a lack of trying.

Leal Ticiana described on of the developments in assays that will drive the next generation of drugs in this challenging subtype of lung cancer.”

Chul Kim:

“Joshua Reuss presenting a challenging case of progression following first-line chemoimmunotherapy. Currently SOC is docetaxel +/- ramucirumab. We urgently need better 2nd line therapies.”

Stephen V Liu:

“Dr. Leal Ticiana at MaTOS24 discusses biomarkers in SCLC. How do we use differential expression of transcriptional regulators? How do we assess the immunosuppressive microenvironment? Can we target MHC-I deficiency?”

Estela Rodriguez:

“More options for 1st line therapy for EGFR+ lung cancer, means more questions.

Who benefits from intensification regimens?
At what long-term toxicities?
What overall survival difference trumps toxicity?”

Eric K. Singhi:

“Jyoti D Patel delivers the keynote talk at MATOS24:

The current landscape of ADCs in NSCLC & SCLC
What’s ahead for the next-generation of ADCs”

Misty Dawn Shields:

“An all-star panel discussion of the management of metastatic non-small cell lung cancer NSCLC with actionable genomic alterations.

Moderator: Edgardo Santos”

Matthew Smeltzer:

“A great Matos24 case discussion with Mary Jo Fidler, Jason Porter, Karen Kelly.”

Luis E. Raez:

“Discussing ROS1 cancer developments, its repotrectenib the first line? ”

Eric K. Singhi:

“Grateful to the co-chairs for the invite to join MATOS24! The case discussions and Q&A sessions were among the most engaging I’ve ever attended. Huge thanks to the one and only Stephen V Liu for always fostering opportunities for meaningful connections!”

Stephen V Liu:

“Case discussions on targeted therapy at MaTOS24 with Drs. Erminia Massarelli, Christine Lovly, Norman Ashraf, Xiuning Le, Julia Rotow, Jessica J Lin, Elaine Shum.”

Xiuning Le:

“Wrapping up MaTOS24 in beautiful Lake Tahoe.

I discussed a patient case with EGFR compound PACC mutation with liver and CNS mets.

Fun to see the debate with Ferdinandos Skoulidis, Biagio Ricciuti (of course on KRAS) and hang out with Boston oncology girls Zosia Piotrowska, Jessica J Lin, Julia Rotow and Elaine Shum.”

For more posts like this visit oncodaily.com